QURE 241115 2.00C (QURE241115C2000) Stock Options, News & Quotes

US OptionsDetailed Quotes

QURE241115C2000

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 5 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

uniQure NV | 10-Q: Quarterly report
SECNov 5 09:11 ET · Announcements
UniQure GAAP EPS of -$0.91 Beats by $0.03, Revenue of $2.29M Misses by $4.77M
Seeking AlphaNov 5 07:20 ET
UniQure: Cash Runway Through End of 2027 >QURE
Dow JonesNov 5 07:10 ET
Earnings Flash (QURE) UNIQURE Reports Q3 Revenue $2.3M
MT NewswiresNov 5 07:07 ET
UniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
GlobeNewswireNov 5 07:05 ET
UniQure 3Q Loss/Shr 91c >QURE
Dow JonesNov 5 07:05 ET

Comments

Tonyco

Oct 17 10:54

$CuriosityStream (CURI.US)$
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$

Stock_Drift

Oct 4 14:13

Gainer Ticks. 3:12pm EST.10/4/24

$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $UP Fintech (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $Ford Motor (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $Chanson International (CHSN.US)$
📊⚡️📊

Stock_Drift

Sep 23 06:10

$uniQure NV (QURE.US)$

Jaguar8

Sep 23 06:06

NEWS

$uniQure NV (QURE.US)$
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce G...

Jaguar8

Aug 15 07:56

NEWS

$uniQure NV (QURE.US)$
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry diseasetreatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the live...